These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18557812)

  • 21. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study.
    Giuliano F; Oelke M; Jungwirth A; Hatzimouratidis K; Watts S; Cox D; Viktrup L
    J Sex Med; 2013 Mar; 10(3):857-65. PubMed ID: 23346990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
    Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
    Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of once-daily tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline.
    Shabsigh R; Seftel AD; Kim ED; Ni X; Burns PR
    J Sex Med; 2013 Mar; 10(3):844-56. PubMed ID: 23035781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of tadalafil efficacy in men with erectile dysfunction: the SURE study comparing two dosing regimens.
    Costa P; Buvat J; Holmes S; Weitckus S; Petto H; Hamidi K; Varanese L
    J Sex Med; 2006 Nov; 3(6):1050-1058. PubMed ID: 17100938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report.
    Liguori G; Trombetta C; De Giorgi G; Pomara G; Maio G; Vecchio D; Ocello G; Ollandini G; Bucci S; Belgrano E
    J Sex Med; 2009 Feb; 6(2):544-52. PubMed ID: 19138360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.
    Young JM; Feldman RA; Auerbach SM; Kaufman JM; Garcia CS; Shen W; Murphy AM; Beasley CM; Hague JA; Ahuja S
    J Androl; 2005; 26(3):310-8. PubMed ID: 15866997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers.
    Carson C; Shabsigh R; Segal S; Murphy A; Fredlund P; Kuepfer C;
    Urology; 2005 Feb; 65(2):353-9. PubMed ID: 15708052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily.
    Rubio-Aurioles E; Kim ED; Rosen RC; Porst H; Burns P; Zeigler H; Wong DG
    J Sex Med; 2009 May; 6(5):1314-23. PubMed ID: 19473285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial.
    Ricardi U; Gontero P; Ciammella P; Badellino S; Valentino F; Munoz F; Guarneri A; Rondi N; Moretto F; Filippi AR; Ragona R; Tizzani A
    J Sex Med; 2010 Aug; 7(8):2851-9. PubMed ID: 21711479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
    Montorsi F; Verheyden B; Meuleman E; Jünemann KP; Moncada I; Valiquette L; Casabé A; Pacheco C; Denne J; Knight J; Segal S; Watkins VS
    Eur Urol; 2004 Mar; 45(3):339-44; discussion 344-5. PubMed ID: 15036680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing.
    Kloner RA; Jackson G; Hutter AM; Mittleman MA; Chan M; Warner MR; Costigan TM; Vail GM
    Am J Cardiol; 2006 Jun; 97(12):1778-84. PubMed ID: 16765134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.
    Montorsi F; Aversa A; Moncada I; Perimenis P; Porst H; Barker C; Shane MA; Sorsaburu S
    J Sex Med; 2011 Sep; 8(9):2617-24. PubMed ID: 21707928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction.
    Goldfischer ER; Kim ED; Seftel AD; Baygani SK; Burns PR
    Urology; 2014 Jun; 83(6):1326-33. PubMed ID: 24726311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study.
    Dean J; Hackett GI; Gentile V; Pirozzi-Farina F; Rosen RC; Zhao Y; Warner MR; Beardsworth A
    J Sex Med; 2006 Jul; 3(4):650-661. PubMed ID: 16839321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction.
    McMahon CG; Carson CC; Fischer CJ; Wang WC; Florio VA; Bradley JD
    J Sex Med; 2006 May; 3(3):504-11. PubMed ID: 16681476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of tadalafil in men with erectile dysfunction following spinal cord injury.
    Giuliano F; Sanchez-Ramos A; Löchner-Ernst D; Del Popolo G; Cruz N; Leriche A; Lombardi G; Reichert S; Dahl P; Elion-Mboussa A; Casariego J
    Arch Neurol; 2007 Nov; 64(11):1584-92. PubMed ID: 17846260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of tadalafil on erectile dysfunction: on-demand versus once-daily dosing].
    Tang YX; Zhou HB; Peng SL; Jiang XZ; He LY; Li DJ
    Zhonghua Nan Ke Xue; 2012 May; 18(5):472-4. PubMed ID: 22741449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
    Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
    J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.